China Medical System Holdings (HK:0867) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
China Medical System Holdings announced the acceptance of their New Drug Application for ruxolitinib phosphate cream, aimed at treating vitiligo, by China’s National Medical Products Administration. The cream showed significant efficacy in a Chinese Real-World Study, outperforming target values with mild to moderate adverse events. This product has potential to help the millions suffering from this chronic autoimmune skin condition in China and has already been made available in Hainan’s Pilot Zone and approved in Macau.
For further insights into HK:0867 stock, check out TipRanks’ Stock Analysis page.